A randomized, double-blind, crossover comparison of atomoxetine and placebo in child outpatients with attention-deficit/hyperactivity disorder, reading disorder, or comorbid attention-deficit/hyperactivity disorder and reading disorder
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder; Learning disorders
- Focus Therapeutic Use
- 13 Apr 2010 Actual number of patients changed from 76 to 121 as reported by ClinicalTrials.gov record.
- 11 Jan 2008 Status changed from recruiting to completed.
- 13 Nov 2005 New trial record.